Concepedia

Author

Konrad Kokowski

München Klinik Bogenhausen

Also Known As

K Kokowski, K. Kokowski, Kokowski, Konrad, Konrad Kokowski

31

Publications

455

Citations

9

H-Index

7

Concepts

All Affiliations

München Klinik BogenhausenGerman Center for Lung ResearchPius Hospital OldenburgKlinikum rechts der IsarNottingham Trent University
KK

About

Konrad Kokowski is an author at München Klinik Bogenhausen specializing in lung cancer, cancer therapeutics, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

183

2

Cancer Therapeutics

2

2

183

3

Lung Cancer

2

2

183

4

Pharmacology

1

1

78

5

Molecular Oncology

1

1

78

Konrad Kokowski

×

9

Publications

426

Citations

9

H-Index

YearCitations

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni,

Annals of Oncology

2021

105

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin,

Annals of Oncology

2023

78

KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Martin Sebastian, Wilfried Eberhardt, Petra Hoffknecht,

Lung Cancer

2021

75

Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial

Gabriele Multhoff, Sophie Seier, Stefan Stangl,

Clinical Cancer Research

2020

60

Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study

Konrad Kokowski, Stefan Stangl, Sophie Seier,

Strahlentherapie und Onkologie

2019

42

Membrane Hsp70—A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition

Stephanie Breuninger, Stefan Stangl, Caroline Werner,

Frontiers in Oncology

2018

32

Afatinib as first-line treatment in patients with <i>EGFR</i>-mutated non-small cell lung cancer in routine clinical practice

W. Brückl, Martin Reck, Frank Griesinger,

Therapeutic Advances in Medical Oncology

2021

12

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

Farastuk Bozorgmehr, Fabian Weykamp, Tobias R. Overbeck,

Annals of Oncology

2023

12

1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study

Johan Vansteenkiste, Egbert F. Smit, Harry J.M. Groen,

Annals of Oncology

2020

10

Page 1